- Home
- GSK vs BDX Comparison
GSK vs BDX Comparison
Compare GSK & BDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | GSK | BDX |
|---|---|---|
| Founded | 1715 | 1897 |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 95.3B | 55.7B |
| IPO Year | N/A | 1962 |
Fundamental Metrics
Financial Performance| Metric | GSK | BDX |
|---|---|---|
| Price | $49.13 | $196.15 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 9 |
| Target Price | N/A | ★ $213.13 |
| AVG Volume (30 Days) | ★ 3.3M | 1.9M |
| Earning Date | 02-04-2026 | 02-04-2026 |
| Dividend Yield | ★ 3.38% | 2.14% |
| EPS Growth | ★ 118.57 | N/A |
| EPS | 1.79 | ★ 5.82 |
| Revenue | ★ $43,237,357,842.00 | $21,840,000,000.00 |
| Revenue This Year | $6.70 | $4.02 |
| Revenue Next Year | $5.10 | $3.37 |
| P/E Ratio | ★ $13.25 | $33.73 |
| Revenue Growth | 2.73 | ★ 8.24 |
| 52 Week Low | $31.72 | $162.29 |
| 52 Week High | $49.44 | $251.99 |
Technical Indicators
Market Signals| Indicator | GSK | BDX |
|---|---|---|
| Relative Strength Index (RSI) | 59.99 | 55.10 |
| Support Level | $48.69 | $194.82 |
| Resistance Level | $49.23 | $198.10 |
| Average True Range (ATR) | 0.57 | 3.61 |
| MACD | -0.06 | -0.32 |
| Stochastic Oscillator | 85.66 | 54.88 |
Price Performance
Historical ComparisonAbout GSK GSK plc (Each representing two)
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, antiviral, and vaccines, and has been growing its presence in oncology and immunology, as well. GSK uses joint ventures to gain additional scale in certain markets like HIV.
About BDX Becton Dickinson and Company
Becton Dickinson is the world's largest manufacturer and distributor of medical surgical products, such as needles, syringes, and sharps-disposal units. The company also manufactures prefilled devices, diagnostic instruments, and reagents, as well as flow cytometry and cell-imaging systems. BD Medical is nearly half of the total business, while BD Life Sciences (26% of 2024 revenue) and BD Interventional (25%) account for the remainder. International revenue accounts for 43% of the company's business.